In brief
The potential tariffs could have significant effects on the prices of essential products, including medicines and medical devices popular in America.
In a bold move aligned with his previous protectionist trade tactics, President-elect Donald J. Trump has threatened to impose substantial tariffs on Denmark unless the country agrees to cede Greenland to the United States. Known as an autonomous territory within the Kingdom of Denmark, Greenland has recently become a focal point in international discussions regarding ownership and strategic interests."You don’t just take territory like that, but they should give it up because we need it for national security," Trump stated, reflecting his administration’s focus on national interests. Despite Denmark's small size and its limited trade volume with the U.S. — exporting $11 billion worth of goods in 2023 against a backdrop of $3 trillion total U.S. imports — the situation raises concerns about specific sectors that could be heavily impacted.Remarkably, a significant portion of Denmark’s exports to the U.S. consists of pharmaceuticals, including life-saving medications and treatments. The country is home to Novo Nordisk, the pharmaceutical giant behind popular weight-loss drugs such as Ozempic and Wegovy. The firm’s manufacturing operations have fundamentally shaped the Danish economy, making it a critical player in the healthcare sector, with a notable contribution to private sector job growth.Should Trump follow through with his tariff threats, American consumers could face increased prices for essential medications. Products like insulin and antibiotics comprise approximately half of Denmark’s exports to the U.S.; thus, potential tariffs could jeopardize their affordability and availability for millions of Americans reliant on these therapies.As Novo Nordisk has been ramping up its production efforts in the U.S. to cater to heightened demand, the company continues to monitor the evolving situation closely, although it refrains from commenting on speculative outcomes. The ramifications of Trump's stance may not only influence the pharmaceutical landscape but also raise broader questions about U.S.-Denmark economic relations, consumer rights, and public health access. As the situation develops, the implications of such tariffs remain uncertain, but the potential risks to everyday American consumers are growing.

